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Abstract
TLRs, including TLR4, have been shown to play a crucial role in cardiovascular inflammatory-based diseases. The main
goal of this study was to determine the potential of FP7, a synthetic glycolipid active as a TLR4 antagonist, to modulate
haematopoietic and non-haematopoietic vascular TLR4 pro-inflammatory signalling. HUVEC, human THP-1 monocytes,
THP-1-derived macrophages, mouse RAW-264.7 macrophages and Angiotensin II-infused apolipoprotein E-deficient
mice were in vitro and in vivo models, respectively. Western blotting, Ab array and ELISA approaches were used to
explore the effect of FP7 on TLR4 functional activity in response to bacterial LPS (in vitro) and endogenous ligands of
sterile inflammation (in vitro and in vivo). Following activation of TLR4, in vitro and in vivo data revealed that FP7 inhibited
p38 MAPK and p65 NF-kB phosphorylation associated with down-regulation of a number of TLR4-dependent pro-
inflammatory proteins. In addition to inhibition of LPS-induced TLR4 signalling, FP7 negatively regulated TLR4 activation
in response to ligands of sterile inflammation (hydroperoxide-rich oxidised LDL, in vitro and Angiotensin II infusion,
in vivo). These results demonstrate the ability of FP7 to negatively regulate in vitro and in vivo haematopoietic and non-
haematopoietic vascular TLR4 signalling both in humans and mice, suggesting the potential therapeutic use of this TLR4
antagonist for pharmacological intervention of vascular inflammatory diseases.
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Introduction
The worldwide incidence of cardiovascular diseases
(CVD) has increased dramatically for the last few dec-
ades because of a variety of health, economic and social
factors.1 At the same time there is a lack of direct phar-
macological prevention or treatment of CVD.
Discovery of drugs for treatment and stabilisation of
these diseases is a worthy challenge, with a significant
commercial impact to relieve a significant global finan-
cial burden from the health services. The pathogenesis
of CVD is complex, involving the interaction of several
fundamental physiological processes; however, it is
believed that sterile inflammation plays a fundamental
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role in all stages of CVD.2 TLRs serve as PRRs within
the immune system and recognise PAMPs and danger-
associated molecular patterns (DAMPs) ligands as
inflammatory triggers. Among these receptors, TLR4
is known to be activated by the Gram-negative bacteria
LPS. Additionally, TLR4 is also activated by endoge-
nous DAMPs, known as ligands of sterile inflamma-
tion, such as heat-shock proteins,3 fibronectins, small
fragments of hyaluronan,4 saturated fatty acids5 and
oxidised low-density lipoprotein (oxLDL).6 TLR4
expression has been described both in haematopoietic
and non-haematopoietic cells.6 Moreover, TLR4 has
been documented to be implicated in the pathogenesis
of inflammatory-related CVD. For example, recent
studies have demonstrated that deletion of the TLR4
gene in haematopoietic and non-haematopoietic cells
protected against CVD.7–10 These findings strongly
support the idea that regulation of TLR4 may be a
novel target for therapeutic control of CVD.
Over the last two decades TLR4 antagonists have
been evaluated in preclinical and clinical studies; how-
ever, none have been approved for clinical use for the
time being.11,12 Therefore, discovery of novel TLR4
modulators is a big challenge with high commercial
and social impact. Recently, we have developed a syn-
thetic anionic glycolipid, named FP7, as a TLR4 antag-
onist.13 FP7 is an MD-2 ligand that binds the
hydrophobic cavity of MD-2 and displaces LPS and
other ligands, thus inhibiting TLR4 activation (forma-
tion of TLR4/MD-2/LPS homodimer).14,15
The main aim of this study was to investigate the
potential of FP7 to modulate human and mouse vas-
cular TLR4 signalling. Our results determined the abil-
ity of FP7 to negatively regulate non-haematopoietic
and haematopoietic TLR4 signalling, suggesting the
potential therapeutic use of this TLR4 antagonist for
treatment of inflammatory CVD.
Materials and methods
Materials
FP7 was prepared in F. Peri laboratories (University of
Milano Bicocca) by multistep organic synthesis, and
the purity and identity of the compound was assessed
by NMR, mass spectrometry and HPLC analyses as
previously described.15 LPS [Salmonella Minnesota
(Re) R595, TLRpureTM] was kindly provided by
Innaxon, Tewkesbury. For in vitro experiments FP7
was reconstituted in DMSO/ethanol (1:1). For in vivo
experiments FP7 was reconstituted in LipodisqTM, a
biodegradable liposomal nano-disc formulation
(Malvern Cosmeceutics, Malvern, UK). FP7 in
LipodisqTM was formulated and prepared by
Innaxon, Tewkesbury.
Preparation of lipid hydroperoxide-rich LDL
Native LDL (2 mg protein/ml) was dialysed at 4C
against phosphate buffer (140 mM NaCl, 8.1 mM
Na2HPO4, 1.9 mM NaH2PO4, and pH 7.4), to
remove residual EDTA, followed by dialysis for 24 h
against MOPS buffer (10 mM MOPS, 150 mM NaCl,
and pH 7.4, treated with washed Chelex-100). The
LDL was then oxidised by dialysis against MOPS
buffer containing 10 lM CuSO4 (both within the bag
and in the surrounding dialysis buffer) for 24 h at 4C
to form hydroperoxide-rich LDL. Oxidation was
stopped by the addition to the dialysis bag of 1 mM
EDTA and the LDL dialysed for a further 24 h against
phosphate buffer containing 100 lM EDTA, filter-
sterilised and stored at 4C.16
Cells maintenance and treatment
HUVEC, purchased from Promocell (Heidelberg,
Germany), were treated in accordance to the com-
pany’s instructions. The cells were maintained at
37C, 5% constant atmospheric condition of CO2
in endothelial cell growth medium 2 (Promocell) in
25 cm2 flasks pre-coated with 1% attachment factor
(Sigma, UK). HUVEC were used between passages
3 and 5. THP-1 cells were obtained from the
European Collection of Animal Cell Cultures
(Salisbury, Wiltshire, UK) and cultured in Roswell
Park Memorial Institute (RPMI) (þ10% heat-
inactivated FBS (HIFBS), þ1% glutamine, þ1% pen-
icillin/streptomycin). Cells were split three times weekly
and maintained at a density of 0.3 106 cells/ml. For
differentiation of THP-1 cells 25 nM of phorbol 12-
myristate 13-acetate (PMA) was added to plated cells
for 3 d before washing three times with fresh medium.
Cells were then left to rest overnight (16 h) before treat-
ment. Mouse RAW-264.7 macrophages were obtained
from Prof Z. Mallat (Cambridge University,
Cambridge, UK) and cultured in DMEM (þ10%
HIFBS, þ1% penicillin/streptomycin). Medium was
changed three times weekly and cells split after reach-
ing 60% to 70% confluence.
All cells were pre-treated with FP7 (0–10 lM) for
1 h, then exposed to LPS (10 or 100 ng/ml) or
hydroperoxide-rich LDL (0–100 lg/ml protein) for 1
or 16 h.
Animal model
All animal experiments were approved by the local
animal research work ethical review board at St
George’s, University of London. Twelve 3-mo-old
Apolipoprotein (Apo) E–/–/C57Bl6 were randomly sep-
arated into three groups.17 Two groups (n¼ 4) were
infused with Angiotensin II (1 lg/min/kg), and the
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third (n¼ 4) was infused with saline. FP7 was
co-administered s.c. (3 mg/kg/d, 50 ll LipodisqTM)
and the remaining two groups were co-administered
s.c. with drug vehicle (50 ll LipodisqTM). At d 3, fol-
lowing Angiotensin II infusion, animals were sacrificed.
Tissue collection and processing
Termination of the experiments was scheduled at d 3
after insertion of the osmotic pumps. Animals were
transcardially perfused, at physiological pressures,
with PBS containing a cocktail of proteinase inhibitors
(Sigma Aldrich, UK) for 10 min at 4C, after which the
aortic tree was dissected at 4C, removing the loose
connective tissue around the exterior of the artery.
The suprarenal segment of the mouse aorta was har-
vested, frozen in liquid nitrogen, and stored at –80C
until processed. Tissues were ground to a fine powder
under liquid nitrogen and then lysed by sonication in a
non-denaturing phosphate lysis buffer [20 mM
sodium phosphate, 137 mM NaCl, 25 mM sodium
b-glycerophosphate, 2 mM sodium pyrophosphate,
2mM EDTA, 10% glycerol, 1% Triton X-100 and pro-
tease inhibitor cocktail (Sigma-Aldrich, UK)]. Cell
lysates were incubated on ice for 20 min and centri-
fuged for 20 min at 10,000 g at 4C. Supernatants
were removed and the pellet of insoluble material dis-
carded. Protein concentration of the cell supernatant
was determined by the bicinchoninic acid method
(Pierce, Rockford, IL, USA).
Western blot analysis of protein expression
and phosphorylation
Cell or tissue lysates (10–20 lg) were separated on a
7.5% TGX gel and transferred to polyvinyldifluoride
membranes (Bio-Rad, UK) and blocked using 5%
(wt/vol) skimmed milk in TBS/0.1% (v/v) Tween-20
for 1 h at room temperature (20C). Blots were incu-
bated overnight at 4C with primary Abs: phospho-p38
(4511), phospho-p65 NF-kB (3031), phospho-JNK
(9255) and b-actin (12262) from Cell Signalling
Technology (NEB, Herts, UK) (1:1000 dilution in
TBS, 1% milk). After washing in TBS/0.1% (v/v)
Tween-20, blots were incubated with HRP-conjugated
Ab at room temperature for 1 h in TBS/0.1% (v/v)
Tween-20 and 5% milk. After the final wash, immuno-
reactivity was visualized using the chemiluminescent
substrate ECL Plus (Healthcare, Bucks, UK).
Densitometric analysis was performed using G-box
software Genetools 4.3.8. (Synoptics UK). The level
of cellular actin was used as a loading control.
ELISA
Human monocyte chemoattractant protein (MCP)-1,
IL-1b, IL-6, IL-8 and mouse macrophage inflammato-
ry protein (MIP)-1c production were measured in cell
and tissue lysates (20 lg protein) or cell culture medium
(10–250 ll) using ELISA kits (RayBiotech, USA) fol-
lowing the manufacturer’s instructions. At the final
stage absorbance was measured at 450 nm using a
microplate reader Tecan v7.1 (Sunrise, Austria).
Protein concentration was determined using the
GraphPad Prism version 7.01.
Statistical analysis
Data were reported as meanSD and analysed with
one-way ANOVA followed by the post-hoc Tukey test
for multiple comparisons using GraphPad Prism ver-
sion 7.01. A value of P< 0.05 was consid-
ered significant.
Results
FP7 inhibits LPS-stimulated TLR4 signalling in human
THP-1 cells
TLR4 signalling has been shown to play a critical role
in the functional activity of immune-competent cells at
any stage of the inflammatory process. It is clear that
prolonged activation of the receptor as a result of the
bioavailability of PAMPs and DAMPs can lead to
chronic inflammation that is associated with develop-
ment and progression of inflammatory diseases. To
study the effect of FP7 on TLR4 signalling in mono-
cytes, we utilised THP-1 cells as an in vitro cell model.
We investigated the potential of FP7 to modulate the
expression of LPS/TLR4-dependent proteins. ELISA
results demonstrated that FP7 negatively regulated
the production of a number of LPS/TLR4-driven
pro-inflammatory proteins (IL-8, IL-6, MIP-1a and
IL-1b) in a concentration-dependent manner in THP-
1 cells (Figure 1a–d). These data showed the ability of
FP7 to effectively reduce TLR4 signalling in THP-1
human monocytes.
FP7 suppresses both LPS and hydroperoxide-rich
LDL-induced TLR4 signalling in human
THP-1-derived macrophages
Macrophages are important immune cells in maintain-
ing tissue integrity and culminating the immune
responses in health and diseases. Plasticity and flexibil-
ity are key features of macrophages and their activation
status was shown to be regulated by TLR4 signalling.18
To determine the effect of FP7 on LPS-induced TLR4
signalling in THP-1-derived macrophages, we analysed
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the activation of p38 MAPK/p65 NF-kB as second
messengers in TLR4 signalling and production of sev-
eral TLR4-dependent pro-inflammatory proteins
released from activated THP-1-derived macrophages.
Initially, we tested the ability of FP7 to modulate
TLR4 signalling in THP-1-derived macrophages in
response to LPS. Immunoblotting results showed that
pre-treatment of THP-1 cells with FP7 (0–10 lM) sig-
nificantly inhibited LPS-induced p38 MAPK and p65
NF-kB phosphorylation in a concentration-dependent
manner (Figure 2a and b). Next, we measured the pro-
duction of TLR4-dependent proteins in the presence or
absence of FP7. As illustrated in Figure 2 (c and d),
ELISA results demonstrated that FP7 negatively regu-
lated the production of LPS/TLR4-driven IL-8 and
IL-1b pro-inflammatory proteins in THP-1-derived
macrophages. To further investigate the effect of FP7
on cytokine production, this compound was adminis-
tered prior to, simultaneously with and after LPS in
THP-1-derived macrophages. Irrespective of the time
of administration, FP7 greatly inhibited LPS-induced
IL-6 and TNF-a production in THP-1 macrophages
(Supplemental Figure 2). These data showed the ability
of this small molecule to reverse LPS/TLR4/cytokine
production post factum.
It is well documented that chronic sterile inflamma-
tion is the major contributor to development of CVD.2
Activation of TLR4 by ligands of sterile inflammation
has been demonstrated in various in vitro/in vivo
models.2,5,6 As oxidised forms of lipoproteins might
play a lead role in development of CVD, in the next
series of experiments we tested the potential of FP7
to modulate TLR4 signalling in response to
hydroperoxide-rich oxidised LDL (oxLDL) in THP-
1-derived macrophages. It has been shown that
oxidised forms of LDL can affect different TLRs,
therefore, we compared these effects with LPS, a spe-
cific TLR4 activator. Initially, tetrazolium dye (MTT)
results revealed that FP7 (10 lM) and oxLDL (up to
100 lg/ml protein) did not have an impact on cell via-
bility (Supplemental Figure 1). In the next series of
experiments our results documented the ability of
oxLDL, but not native LDL, to induce production of
IL-8 and IL-1b in a concentration-dependent manner
in THP-1-derived macrophages (Figure 2c and d). In
contrast, pre-treatment with FP7 (10 lM) efficiently
800
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Figure 1. FP7 down-regulates LPS/TLR4-induced cytokine production in THP-1 monocytes. THP-1 monocytes were pre-incubated
with FP7 (0–10 lM) for 1 h and then exposed to LPS (100 ng/ml) for 16 h. ELISA was used to measure cytokine production: IL-8 (a),
IL-6 (b), IL-1b (c) and macrophage inflammatory protein (MIP)-1a (d) following 16 h exposure to LPS. Data are mean SD, n¼ 3 at
each data point. Significant results are indicated as *P< 0.05, **P< 0.01 and ***P< 0.001.
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inhibited production of oxLDL-driven IL-8 and IL-1b
production in THP-1-derived macrophages. These
results clearly demonstrated the potential of FP7 to
negatively regulate TLR4 signalling in response
to ligands of sterile and non-sterile inflammation in
human THP-1-derived macrophages.
FP7 inhibits LPS-induced TLR4 signalling in mouse
RAW-264.7 macrophages
There is a good body of evidence that protein sequen-
ces of human TLR4 and MD-2 are not completely con-
served across species and that might reflect the
functional activity of the receptor in response to dis-
tinct ligands including immune modulators.19 This can
present real difficulties in validating immune-
modulators in preclinical models which can affect
human but not mouse TLR4. Having shown that
FP7 can inhibit human TLR4, in the next series of
experiments we tested the ability of FP7 to affect
mouse TLR4 functional activity in mouse RAW-
264.7 macrophages. We applied the same experimental
design as with THP-1 cells, based on two readouts
(activation of TLR4 second messengers and production
of TLR4-dependent pro-inflammatory proteins).
Initially, FP7 (up to 10 lM) did not affect cell viability
(Supplemental Figure 1). Immunoblotting data
revealed that FP7 significantly inhibited LPS/
TLR4-induced p65 NF-kB and p38 MAPK
phosphorylation in a concentration-dependent
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Figure 2. FP7 inhibits LPS and hydroperoxide-rich oxidised LDL (oxLDL)-induced TLR4 signalling in THP-1-derived macrophages.
Cells were differentiated with PMA and pre-incubated with FP7 (0–10 lM) for 1 h and then exposed to LPS (10 ng/ml) for 60 min.
Western blot was used to measure p65 NF-kB (a) and p38 MAPK (b) phosphorylation. Actin was used as a loading control. THP-1
macrophages were exposed to LPS (10 ng/ml), native low-density lipoprotein (LDL) (nLDL, 100 mg/ml protein) or oxLDL( 0–100 mg/
ml protein) in the presence or absence of FP7 (10 mM). IL-8 (c) and IL-1b (d) production was measured in the medium after 16 h via
ELISA. Data are mean SD, n¼ 3 at each data point. Significant results are shown as *P< 0.05 and ***P< 0.001.
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manner (Figure 3a and b), which was associated with
down-regulation of TLR4-dependent cytokine IL-6
(Figure 3c). Interestingly, we found that FP7 was
not able to affect the production of LPS-driven KC
(mouse IL-8) in mouse macrophages, suggesting that
FP7 displayed a selective inhibitory effect between
human and mouse TLR4. These results clearly validat-
ed the potential of this small molecule to negatively
regulate mouse TLR4 signalling, suggesting its applica-
tion in rodent models for treatment of inflammatory-
based CVD.
FP7 negatively regulates LPS-induced TLR4 signalling
in HUVEC
Vascular endothelial TLR4 has been shown to play a
critical role in initiation and progression of CVD.
Endothelial cells use TLR4 signalling to produce pro-
inflammatory proteins which initiate an inflammatory
process by activating and attracting haematopoietic
cells such as monocytes, macrophages or neutrophils.
To test the potential of FP7 to modulate endothelial
TLR4 signalling pathways, we utilised HUVEC as an
in vitro model. To determine the effect of FP7 on LPS-
induced TLR4 signalling in HUVEC, we analysed the
activation of p38 MAPK/p65 NF-kB as second mes-
sengers in TLR4 signalling and production of MCP-1,
a well-known TLR4-dependent chemokine produced
from endothelial cells in response to LPS. Initially,
Western blot data revealed that p38 MAPK and p65
NF-kB phosphorylation were elevated in response to
LPS in HUVEC (Figure 4a and b). In contrast, FP7
significantly inhibited LPS-stimulated p38 MAPK/p65
NF-kB phosphorylation. Further, ELISA results dem-
onstrated that FP7 blocked LPS-driven MCP-1 expres-
sion in HUVEC (Figure 4c). Overall, these data
demonstrated that FP7 was a negative regulator of
TLR4 signalling in HUVEC.
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Figure 3. FP7 inhibits LPS-induced TLR4 signalling in mouse RAW-264.7 macrophages. Cells were pre-incubated with FP7 (0–10 lM)
for 1 h and then exposed to LPS (100 ng/ml) for 60 min ((a) and (b)) or 16 h ((c) and (d)). Cell lysates were analysed for p65 NF-kB (a),
p38 MAPK (b) phosphorylation, and cell media were analysed for IL-6 (c) and keratinocyte chemoattractant (KC) expression (d) using
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Significant results are indicated as *P< 0.05, **P< 0.01 and ***P< 0.001.
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FP7 down-regulates TLR4 signalling in mouse aorta
in response to sterile inflammation
Prevention of experimental atherosclerosis, aneurysm
and heart failure by deletion of TLR4 was previously
reported, suggesting that TLR4 may represent a novel
therapeutic target for pharmacological treatment of
CVD.8 Having shown that FP7 can negatively regulate
mouse TLR4 signalling, in the next series of experi-
ments we tested the efficacy of FP7 to modulate
in vivo vascular TLR4 signalling pathways. For this
purpose, we utilised the Angiotensin II-infusion in the
Apo E-deficient mouse as an in vivo model. We have
previously reported that the infusion of Angiotensin II
in Apo E-deficient mice induced an inflammatory pro-
cess which was associated with activation of TLR4 sig-
nalling and production of pro-inflammatory proteins
which peaked at 72 h in mouse aorta.17,20 Therefore,
we investigated the effect of FP7 on TLR4 signalling in
the mouse aorta at 72 h of Angiotensin II infusion.
Bearing in mind the poor solubility of FP7 in aqueous
solutions, we used a LipodisqTM carrier technology for
an in vivo administration of FP7 in Apo E-deficient
mice. The results from Western blot analysis of
proteins isolated from the mouse aorta revealed the
ability of FP7 to significantly inhibit Angiotensin
II-stimulated JNK phosphorylation, a well-known
mediator of TLR4 signalling (Figure 5a). Further,
we explored whether FP7 could have an impact
on Angiotensin II-driven production of pro-
inflammatory proteins in the mouse aorta. Mouse
tissue lysates were analysed on a mouse inflammation
Ab array (containing 40 pro-inflammatory proteins).
The semi-quantitative analysis demonstrated that FP7
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Figure 4. FP7 inhibits LPS-induced TLR4 signalling in HUVEC. Cells were pre-incubated with FP7 (0–5 lM) for 1 h and then exposed
to LPS (100 ng/ml) for 60 min ((a) and (b)) or 16 h (c). Cell lysates were analysed for p65 NF-kB (a) and p38 MAPK (b) phos-
phorylation and monocyte chemoattractant protein (MCP)-1 (c) expression using immunoblotting and ELISA analyses, respectively.
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inhibited, to various extents, the expression of 15/25
Angiotensin II-driven pro-inflammatory proteins
(Supplemental Table 1). Finally, we validated the
blocking effect of FP7 on MIP-1c production (a well-
known chemokine for attraction and differentiation of
circulating monocytes). ELISA results showed that
FP7 greatly decreased production of MIP-1c in the
mouse aorta (Figure 5b). These data demonstrated
that FP7 negatively regulated mouse TLR4 signalling
(in vivo), suggesting that this molecule could be suc-
cessfully used in preclinical models for treatment
of CVD.
Discussion
Inflammation has been documented as a critical event
in a variety of CVD. In this regard, a number of studies
have shown the essential role of TLR4 in several car-
diovascular pathologies, suggesting that the modula-
tion of TLR4 signalling pathways will be beneficial
for treatment.21,22 Pharmacological intervention using
TLR4 antagonists has been a challenging approach for
the last two decades; however, these candidates failed
in different stages of clinical trials and therefore a
generation of new TLR4 modulators is of great
interest.11,12
Recently, it has been reported that the MD-
2-directed synthetic TLR4 antagonist FP7 inhibited
TLR4 function and glycolytic re-programming of den-
dritic cells, and protected mice from death due to
TLR4-dependent influenza infection.23 In this study
we showed that FP7 had the potential to inhibit hae-
matopoietic and non-haematopoietic TLR4 signalling
in response to distinct TLR4 ligands which are associ-
ated with the pathogenesis of CVD.
TLR4 plays an important role in prolonged and
sustained activation of the monocytes/macrophage
system which is fundamental for initiation and progres-
sion of inflammatory diseases. In this study we demon-
strated the potential of the TLR4 antagonist FP7 to
block MyD88-dependent TLR4 signalling both in
human monocytes and macrophage. We showed the
ability of FP7 to negatively regulate TLR4 signalling
to second messengers (p65 NF-kB/p38 MAPK) and
pro-inflammatory proteins secretion (IL-8, IL-6, IL-
1b, MIP-1a). Importantly, we also showed that irre-
spective of the time of administration (prior, simulta-
neously or after LPS stimulation), this small molecule
inhibited the production of LPS/TLR4-driven pro-
inflammatory cytokines (IL-6 and TNF-a). These in
vitro results complemented the data obtained from an
in vivo experimental model, where co-administration of
FP7 and Angiotensin II infusion blocked TLR4 func-
tional activity in Apo E-deficient mouse aortas. While
the in vitro effect of pre-incubation or co-incubation
with FP7 could be explained by competition between
LPS and FP7 to bind MD-2 and displaced LPS,24 the
blocking effect of FP7 administered after LPS requires
a different explanation as the LPS/MD-2/TLR4 active
complex can activate the second messengers (MAPK or
NF-kB) in a few minutes. Further studies to investigate
the effect of FP7 on downstream targets in TLR4 sig-
nalling, including TLR4 internalisation and degrada-
tion, are needed.
We report that this small molecule could negatively
modulate TLR4 activation in response to ligands of
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administered s.c. up to 72 h. Tissue samples from mouse aorta were prepared at 72 h, and soluble proteins were analysed for JNK
phosphorylation (a) and MIP-1c expression (b) using immunoblotting and ELISA analyses, respectively. Actin was used as a loading
control. Data are mean SD, n¼ 3/4 mice at each data point, *P< 0.05.
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non-sterile (LPS) and sterile inflammation (oxLDL),
showing that FP7 blocks TLR4-mediated inflammato-
ry processes triggered by distinct TLR4-associated
danger signals.
Although the protein sequence of TLR4 is conserved
across species, the sequence of the MD-2 adaptor is
different, so that species-specific ligand discrimination
or adaptor selection has been observed between human
and mouse TLR4.19 For certain synthetic and natural
lipid A variants, such as lipid IVa, when transferring
from the human to murine TLR4/MD-2/CD14 system,
an antagonistic effect could switch to an agonistic
effect.25 The species-specificity is due to different posi-
tioning of the same ligand, thus causing differential
activity.24 Our data strongly confirm the ability of
FP7 to block both human and mouse TLR4 signalling
in macrophages. In this study we demonstrated the effi-
cacy of FP7 to negatively regulate TLR4 signalling in
different haematopoietic cells. The fact that FP7 was
shown to block TLR4/MD-2/CD14 interactions based
on its high affinity to bind MD-2 may explain the spe-
cific biochemical properties of this small molecule.23,24
We and other groups have found that early stages of
vascular disease development are associated with acti-
vation of MAPK and production of pro-inflammatory
proteins in the experimental model of an Angiotensin II
infusion in hypercholesterolaemic mice.20,26 TLR4 sig-
nalling plays an essential role in propagation of inflam-
mation and mediates production of a large proportion
of the pro-inflammatory proteins production. It has
been reported that TLR4 deficiency attenuated aneu-
rysm and atherosclerosis development, suggesting that
TLR4 signalling is fundamental in related vascular
pathologies.8 TLR4 signalling exerted effects through
non-haematopoietic cell types, suggesting that vascular
cells might use the TLR4 signalling network in
response to an inflammatory environment.8 In this
regard we have previously reported that another syn-
thetic TLR4 antagonist (IAXO-102) inhibited TLR4
signalling in HUVEC and protected against experimen-
tal abdominal aortic aneurysm development.20 In this
study we showed the potential of the synthetic TLR4
antagonist FP7 to block TLR4 signalling in non-
haematopoietic vascular cells.
Having shown that FP7 can affect mouse TLR4,
further we examined the potential of FP7 to modulate
in vivo TLR4 signalling utilising a well-established
model of an Angiotensin II infusion in the hypercho-
lesterolaemic Apo E-deficient mouse. Using the nano-
carrier LipodisqTM, we were able to deliver FP7 by
improving the compound’s solubility in aqueous and
physiological solvents. We have successfully used a
similar nano-carrier approach for administration of
IAXO-102 (TLR4 antagonist) with a poor solubility,
for which pharmacokinetic studies demonstrated that
the dose of 3 mg/kg/d was sufficient to produce positive
signal and drug distribution among several organs.20
Several studies from the literature, including our
data, prove the role of MAPK in CVD develop-
ment.19,20,24 JNK has been shown as an important
target for Angiotensin II/TLR4 signalling leading to
activation of c-jun/c-fos and production of a number
of pro-inflammatory proteins. In this regard, it has
been reported that inhibition of JNK markedly affects
the initiation and progression of CVD.27,28 Previously,
we have identified JNK as a target by which rosiglita-
zone and IAXO-102 inhibited Angiotensin II/TLR4-
induced inflammatory responses in the mouse aorta
and reduced markedly aortic aneurysm formation.17,20
In this study FP7 efficiently inhibited JNK phosphor-
ylation and negatively regulated a large number of
TLR4-dependent pro-inflammatory proteins in the
mouse aorta. These results clearly demonstrated the
ability of FP7 to block the initiation of Angiotensin
II-driven sterile inflammation in the mouse aorta.
Further studies using histological and immunohisto-
chemistry approaches to demonstrate the impact of
FP7 on aortic tissue remodelling and identification of
specific cells responsible for a propagation of TLR4
signalling at late stages of the inflammatory process
in the Angiotensin II-infused Apo E-deficient mouse
model are needed.
In support to our findings, Perrin-Cocon and col-
leagues recently reported that FP7 can block TLR4
activity in response to another trigger of sterile inflam-
mation (high mobility group box 1 protein, HMGB-1)
in dendritic cells.23 Furthermore, using the dextran-
sulphate-sodium-induced rodent model of colitis, we
recently demonstrated that FP7 efficiently blocks the
inflammatory process in this preclinical model of
inflammatory bowel disease (unpublished data). In
the literature, it has been shown that Angiotensin II
infusion may trigger sterile inflammation by generation
of reactive oxygen species leading to formation of
oxLDL in hyperlipidaemic mice.29 In relation of this,
we suggested that FP7 might inhibit TLR4 signalling
activated by ligands of ‘sterile’ inflammation, such as
oxLDL, in the mouse model infused with Angiotensin
II. In support of this notion, our data showed that this
small molecule inhibited TLR4 signalling in response
to oxLDL in human THP-1-derived macrophages.
This is an important issue because different TLR4
ligands have a specific signature in production of
TLR4-dependent proteins leading to various outcomes.
Overall, these data confirmed the potential of FP7 to
negatively modulate in vitro and in vivo TLR4 signal-
ling in response to DAMPs-triggered sterile inflamma-
tion. Furthermore, this study also shows the potential
of FP7 to inhibit TLR4 signalling in response to dis-
tinct TLR4 ligands such as LPS or oxLDL.
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In conclusion, the results from this study demon-
strated that the synthetic TLR4 antagonist FP7 was
effective in blocking haematopoietic and non-
haematopoietic vascular TLR4 signalling, suggesting
the potential of this small molecule for pharmacologi-
cal intervention of CVD and other inflammatory dis-
eases. Future work, based on the experimental model
(in vivo) used in this study, will be focused on preclin-
ical validation of FP7 for treatment of atherosclerosis
and aneurysms.
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